A Double Blind Study Of Its Use In Degenerative Arthritis -- MSM Research Data

METHYL-SULFONYL-METHANE (M.S.M.)
A Double Blind Study Of Its Use In Degenerative Arthritis
(A Preliminary Correspondence)
By Ronald M. Lawrence, M.D., Ph.D.
Assistant Clinical Professor
U.C.L.A. School of Medicine
Los Angeles, California

     A total of sixteen patients were studied over a period of four months. Initially twelve patients were admitted to the study and subsequently (two months later) an additional four patients were added to the study group. The initial twelve patients were divided as follows. Eight were given the M.S.M., while four received the placebo. Later, the additional four patients were divided into two on M.S.M. and two on placebo. Totally, therefore, we had ten patients on M.S.M. and six patients on placebo.

Criteria for Selection
     Patients ranged from age 55 to age 78. All patients had x-ray evidence of degenerative joint disease (degenerative arthritis). All patients had pain in the involved area ranging from four weeks to six months. Most of the patients had tried non-steroidal anti-inflammatory drugs or aspirin type compounds. None had taken steroids either orally or by injection. All non-steroidal anti-inflammatory drugs or other anti-arthritic medications or alternative health remedies were stopped a least three days prior to their entering the study.
     Patients were randomly chosen by lot and assigned to either the active (M.S.M.) group or the placebo group. The treating physician did not have knowledge as to which patient received which agent until after the completion of the study. Records were kept by an independent evaluator until the study was terminated. Both the patients and the physicians were blinded.
     Of the eight patients on LIGNISUL MSM™, two had osteoarthritis in their hands, three had lumbar degenerative joint disease, two had degenerative arthritis in their knees, and one had arthritis in the shoulder.
     Of the six patients who received the placebo, two had degenerative arthritis in the knees, two had lumbar degenerative joint disease, one had degenerative arthritis in the hip, and one had osteoarthritis in the neck.

Dosage
     Patients were instructed to take two capsules on an empty stomach in the A.M. after arising and one capsule before lunch. This constituted a 2250 milligram dose of LIGNISUL MSM™ daily and zero dose of M.S.M. on the placebo.

Measurement
     Each patient was administered a visual analog scale (V.A.S.) which consisted of a I 0-cm line anchored at one end by a label of "no pain" and at the other end a label of "pain as bad as could possibly be." The scoring is accomplished by having the patient mark the line indicating pain intensity, and the line is then measured to the mark on a I -100 scale (9).

Results
     The V.A.S. was completed by each patient at the four week and at the six week visit. Records were measured by an independent evaluator.
     At the four week visit, the patients on the LIGNISULmsi4rm showed a 60 percent improvement on average, while at the six week V.A.S. evaluation the patients showed and 82 percent improvement in pain on average.
     Those on the placebo showed an improvement of 20 percent on average at four weeks and an 18 percent improvement on average at six weeks.

ABSTRACT
     This preliminary simple study was performed to initially evaluate 16 patients suffering from degenerative arthritis as to the effect of using LIGNISUL MSM™ to control their pain. Eight patients, randomly chosen, were treated with 2250 mgms of M.S.M. per day. Six patients received placebo capsules. Results indicate a better than 80 percent control of pain within six weeks of beginning the study, while only two patients showed a minimal improvement (less than 20 percent) on the placebo. Although this was only a simple preliminary study, it appears that a more intensive investigation of M.S.M. is warranted. A larger group of arthritic patients an additional measurement evaluation (such as range of motion, etc.) should be utilized in such a future study. LIGNISUL MSM™ may offer a significant new nutritional substance for the control of arthritic pain as a safe, non-toxic method.
References
1. Lovelock, J.E. et al. Nature, Vol. 237, p452, 1972
2. Williams, K.I.H. et al. Arch Biochern Biophys, Vol. 113, p251, 1966
3. Jacob, S.W. and Herschler, R., Ann NY Acad Sci, Vol. 411, pxii 1983
4. Richmond, V.L., J Nutrition, Vol. 116 NO. 6, June, 1986
5. Deichman, W.B. & Gerarde, H.W. "Toxicology of Drugs &
     Chemicals, 4bEdition, Arcadia Press, 1969
6. Jacob, S.W., Oregon Health Sciences University, Portland, Oregon,
     Personal communication
7. Jacob, S.W., Oregon Health Sciences University, Portland, Oregon,
     personal communication
8. Rizzo, R. et al. Jour Exp Zool, 1995 September, 1,273(l):82-6
9. Carlson, A.M. Pain, 16:86, 1983

[competition/_private/navbar.htm]

[FrontPage Save Results Component]

Please provide the following contact information:

First name required

Last name required

Middle initial

Information
Request

Title

Organization

Work Phone

Home Phone

FAX

E-mail required

URL

Address 1 requested

Address 2

City requested

State/Province requested

Zip Code requested

Countryrequested
How Did You Find This Web Site?
Select one

What do you think of this site or ... ? I promise to answer your comments, personally.

Dear Karl,

Click here to add the Wednesday Letter as a Channel on your desktop. If your browser is so-equipped, you will be guided through a series of simple questions (about subscription information). Depending on your choices you can show the Vibrant Life Wednesday Letter as one of your "active channels" which will automatically download the new Wednesday Letter every month. In this way you can have the Wednesday Letter delivered to your desktop during the night (or your schedule) for immediate viewing in your browser. You can turn on or off this channel, at will, and delete the channel from your desktop at any time. With this feature operating you can click on the Wednesday Letter channel at any time to read the most recent copy of this electronic letter.

You can reach B&B International in many ways, including by mail to B&B International, 1831 N. Bel Aire Drive, Burbank, CA 91504. Within the US and Canada, use the toll free number: (800) 523-4521, the local number: (818) 558-1799, the FAX: (818) 558-7299, eMail to karl@karlloren.com or any one of the hundreds of message forms throughout the web site. B&B International normally ships the same day we get an order. There are message forms on many of the 2000+ pages on this site where you can communicate with B&B International.

Copyright © May 20, 2008 6:24 AM by Karl Loren on behalf of Vibrant Life, ALL RIGHTS RESERVED. Permission is granted for non-commercial downloading, copying, distribution or redistribution on two conditions: One, that some form of copyright notice is included in every copy distributed or copied, showing the copyright belonging to Vibrant Life, Burbank, CA, at www.oralchelation.com . The second condition is that the material is not to be used for any purpose contrary to the purposes and objectives of this site. This permission does not extend to materials on this site which are copyrighted by others.

[FrontPage Save Results Component]

Please provide the following contact information:

First name required

Last name required

Middle initial

Information
Request

Title

Organization

Work Phone

Home Phone

FAX

E-mail required

URL

Address 1 requested

Address 2

City requested

State/Province requested

Zip Code requested

Countryrequested
How Did You Find This Web Site?
Select one

What do you think of this site or ... ? I promise to answer your comments, personally.

Dear Karl,

[FrontPage Save Results Component]

Please provide the following contact information:

First name required

Last name required

Middle initial

Information
Request

Title

Organization

Work Phone

Home Phone

FAX

E-mail required

URL

Address 1 requested

Address 2

City requested

State/Province requested

Zip Code requested

Countryrequested
How Did You Find This Web Site?
Select one

What do you think of this site or ... ? I promise to answer your comments, personally.

Dear Karl,

[FrontPage Save Results Component]

Please provide the following contact information:

First name required

Last name required

Middle initial

Information
Request

Title

Organization

Work Phone

Home Phone

FAX

E-mail required

URL

Address 1 requested

Address 2

City requested

State/Province requested

Zip Code requested

Countryrequested
How Did You Find This Web Site?
Select one

What do you think of this site or ... ? I promise to answer your comments, personally.

Dear Karl,

First name	required
Last name	required
Middle initial
Information Request
Title
Organization
Work Phone
Home Phone
FAX
E-mail	required
URL
Address 1	requested
Address 2
City	requested
State/Province	requested
Zip Code	requested
	Countryrequested How Did You Find This Web Site? Select one